İlkay Küçükgüzel
Marmara University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by İlkay Küçükgüzel.
European Journal of Medicinal Chemistry | 2009
Sevgi Karakuş; Ş. Güniz Küçükgüzel; İlkay Küçükgüzel; Erik De Clercq; Christophe Pannecouque; Graciela Andrei; Robert Snoeck; Fikrettin Şahin; Omer Bayrak
Due to a continuing effort to develop new antiviral agents, a series of 1-[4-(methanesulfonamido)-3-phenoxyphenyl]-3-alkyl/aryl thioureas 3a-i have been synthesized by the reaction of alkyl/aryl isothiocyanates with 4-amino-2-phenoxymethanesulfonanilide. These derivatives were structurally characterized by the use of spectral techniques and evaluated for their anticancer and antiviral activities. None of the tested compounds showed significant anticancer properties on A549 and L929 cell lines. All synthesized compounds 3a-i were evaluated in vitro against HIV-1 (IIIB) and HIV-2 (ROD) strains in MT-4 cells, as well as other selected viruses such as HSV-1, HSV-2, Coxsackie virus B4, Sindbis virus and varicella-zoster virus using HEL, HeLa and Vero cell cultures. Compound 3b was able to block HIV replication with almost 100% maximum protection at 125 microg/ml, and IC(50) values of 54.9 microg/ml and 65.9 microg/ml against HIV-1 and HIV-2, respectively.
European Journal of Medicinal Chemistry | 2013
İlkay Küçükgüzel; Gökhan Satılmış; K.R. Gurukumar; Amartya Basu; Esra Tatar; Daniel B. Nichols; Tanaji T. Talele; Neerja Kaushik-Basu
Hepatitis C virus (HCV) NS5B polymerase is an important and attractive target for the development of anti-HCV drugs. Here we report on the design, synthesis and evaluation of twenty-four novel allosteric inhibitors bearing the 4-thiazolidinone scaffold as inhibitors of HCV NS5B polymerase. Eleven compounds tested were found to inhibit HCV NS5B with IC₅₀ values ranging between 19.8 and 64.9 μM. Compound 24 was the most active of this series with an IC₅₀ of 5.6 μM. A number of these derivatives further exhibited strong inhibition against HCV 1b and 2a genotypes in cell based antiviral assays. Molecular docking analysis predicted that the thiazolidinone derivatives bind to the NS5B thumb pocket-II (TP-II). Our results suggest that further optimization of the thiazolidinone scaffold may be possible to yield new derivatives with improved enzyme- and cell-based activity.
Medicinal Chemistry | 2006
Fatma Kandemirli; Nathali Shvets; Seda Ünsalan; İlkay Küçükgüzel; Sevim Rollas; Vasyl Kovalishyn; Anatholy Dimoglo
Antituberculosis activity of several 5-(4-aminophenyl)-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones (1-9) and their thiourea derivatives (10-31) were screened for their antimycobacterial activities against Mycobacterium tuberculosis H37Rv using the BACTEC 460 radiometric system. Of the synthesized compounds, 10-12, 30 were the most active derivatives exhibiting more than 90 % inhibition of mycobacterial growth at 12.5 microg/mL. Structure-activity relationships study was performed for the given series by using the Electronic-Topological Method combined with Neural Networks (ETM-NN). A system of prognosis was developed as the result of training associative neural network (ASNN) using weights of pharmacophoric fragments as descriptors. Descriptors were calculated by the projection of ETM compound and pharmacophoric fragments on the elements of Kohonens self-organizing maps (SOM). From the detailed analysis of all compounds under study, the necessary requirements for a compound to possess antituberculosis activity were formulated. The analysis have shown that any requirements violation for a molecule implies a considerable decrease or even complete loss of its activity.
Archiv Der Pharmazie | 2015
Gizem Çakır; İlkay Küçükgüzel; Rupa Guhamazumder; Esra Tatar; Dinesh Manvar; Amartya Basu; Bhargav A. Patel; Javairia Zia; Tanaji T. Talele; Neerja Kaushik-Basu
In continuation of our efforts to develop new derivatives as hepatitis C virus (HCV) NS5B inhibitors, we synthesized novel 5‐arylidene‐4‐thiazolidinones. The novel compounds 29–42, together with their synthetic precursors 22–28, were tested for HCV NS5B inhibitory activity; 12 of these compounds displayed IC50 values between 25.3 and 54.1 µM. Compound 33, an arylidene derivative, was found to be the most active compound in this series with an IC50 value of 25.3 µM. Molecular docking studies were performed on the thumb pocket‐II of NS5B to postulate the binding mode for these compounds.
Biological & Pharmaceutical Bulletin | 2016
Esra Tatar; Sevgi Karakuş; Şükriye Güniz Küçükgüzel; Sinem Öktem Okullu; Nihan Ünübol; Tanıl Kocagöz; Erik De Clercq; Graciela Andrei; Robert Snoeck; Christophe Pannecouque; Sadık Kalaycı; Fikrettin Şahin; Dharmarajan Sriram; Perumal Yogeeswari; İlkay Küçükgüzel
In view of the emergence and frequency of multidrug-resistant and extensively drug-resistant tuberculosis and consequences of acquired resistance to clinically used drugs, we undertook the design and synthesis of novel prototypes that possess the advantage of the two pharmacophores of thiourea and 1,3,4-thiadiazole in a single molecular backbone. Three compounds from our series were distinguished from the others by their promising activity profiles against Mycobacterium tuberculosis strain H37Rv. Compounds 11 and 19 were the most active representatives with minimum inhibitory concentration (MIC) values of 10.96 and 11.48 µM, respectively. Compound 15 was shown to inhibit M. tuberculosis strain H37Rv with an MIC value of 17.81 µM. Cytotoxicity results in the Vero cell line showed that these three derivatives had selectivity indices between 1.8 and 8.7. In order to rationalize the biological results of our compounds, molecular docking studies with the enoyl acyl carrier protein reductase (InhA) of M. tuberculosis were performed and compounds 11, 15, and 19 were found to have good docking scores in the range of -7.12 to -7.83 kcal/mol.
European Journal of Drug Metabolism and Pharmacokinetics | 2005
Ş. Güniz Küçükgüzel; İlkay Küçükgüzel; Başak Oral; Sena Sezen; Sevim Rollas
SummaryNimesulide (4-nitro-2-phenoxymethanesulfonanilide) is an atypical NSAID lacking a carboxylic acid moiety. It has a good gastric tolerability due to selective inhibition of COX-2. The study objectives in the present work were to characterize the metabolism of nimesulide in rat plasma at certain time intervals. In vitro studies were also carried out to examine if nitroreduction takes place in vitro using rat hepatic subcellular fractions (microsomal and S9 fraction) besides aromatic hydroxylation. This communication describes detection and characterization of nimesulide metabolites isolated from plasma and hepatic subcellular post-incubates by the use of HPLC-UV/diode array and LC-MS/MS. Hydroxynimesulide was the major metabolite both in vivo and in vitro whereas nitroreduction was observed only in vitro with subcellular fractions under anaerobic conditions.
Farmaco | 1999
İlkay Küçükgüzel; Mert Ülgen; John W. Gorrod
In the present study, the in vitro microsomal metabolism of a tertiary aniline, N-benzyl-N-methylaniline (NBNMA) was studied to determine whether this compound produces an amide derivative (benzoyl) together with N-dealkylation and C- and N-oxidation products as metabolites. The preparations of the corresponding potential metabolites were undertaken and were separated using TLC and HPLC. Incubations were performed using rat microsomal preparations fortified with NADPH. The substrate and its potential metabolites were extracted into dichloromethane in the presence of NaCl and examined by TLC and HPLC-UV. The results indicated that NBNMA did not produce the corresponding amide (benzoyl derivative) or N-oxide metabolite but was dealkylated to the corresponding secondary amine. Two p-hydroxylated phenolic metabolites were also observed. These findings support the concept that nitrones are essential intermediate metabolites for the formation of amides from secondary aromatic amines (chemical rearrangement to amide via an oxaziridine intermediate). The carbinolamine produced from NBNMA does not seem stable enough to allow further oxidation to the amide and therefore this intermediate is broken down to the dealkylation products. N-Dealkylations and p-hydroxylations are major metabolic reactions following in vitro hepatic microsomal metabolism of the benzylic tertiary aniline, NBNMA.
Archiv Der Pharmazie | 2013
Esra Tatar; İlkay Küçükgüzel; Dirk Daelemans; Tanaji T. Talele; Neerja Kaushik-Basu; Erik De Clercq; Christophe Pannecouque
In accordance with our antiviral drug development attempt, acylhydrazone derivatives bearing amino acid side chains were synthesized for the evaluation of their antiviral activity against various types of viruses. Among these compounds, 8S, 11S, and 12S showed anti‐HIV‐1 activity with a 50% inhibitory concentration (IC50) = 123.8 µM (selectivity index, SI > 3), IC50 = 12.1 µM (SI > 29), IC50 = 17.4 µM (SI > 19), respectively. Enantiomers 8R, 11R, and 12R were inactive against the HIV‐1 strain IIIB. Hydrazones 8S, 11S, and 12S which were active against HIV‐1 wild type showed no inhibition against a double mutant NNRTI‐resistant strain (K103N;Y181C). Molecular docking calculations of R‐ and S‐enantiomers of 8, 11, and 12 were performed using the hydrazone‐bound novel site of HIV‐1 RT.
Drug metabolism and drug interactions | 1997
Mert Ülgen; Ufuk Ozer; İlkay Küçükgüzel; J. W. Gorrod
The in vitro hepatic microsomal metabolism of two tertiary anilines, N-benzyl-N-ethylaniline (NBNEA) and N-benzyl-N-ethyl-p-toluidine (NBNEPT), was examined in order to determine whether these compounds produce amide derivatives (benzoyl or acetyl) in addition to N-dealkylation and N-oxidation products as metabolites. The preparation of these tertiary anilines and their corresponding potential metabolites was undertaken. The amines and metabolites were separated using TLC and HPLC. Incubations were performed using hamster microsomal preparations fortified with NADPH. The substrates and their potential metabolites were extracted into dichloromethane and examined by TLC and HPLC. The metabolic process of particular interest was the formation of amides from NBNEA and NBNEPT. The results from these experiments indicated that neither tertiary aniline (NBNEA and NBNEPT) produced amide (acetyl or benzoyl) or N-oxide metabolites. These substrates were dealkylated to the corresponding secondary amines via debenzylation and de-ethylation. Uncharacterised metabolites observed with substrates are proposed to be phenolic (for NBNEA) and hydroxymethyl (for NBNEPT). These findings support the concept that: nitrones are essential intermediates for the formation of amides from secondary aromatic amines (chemical rearrangement to amide via an oxaziridine intermediate); carbinolamines produced by NBNEA and NBNEPT are not stable enough to allow further oxidation to amides and therefore these intermediates are broken down to dealkylated products. The results are discussed in relation to the mechanism of metabolic amide formation from amines.
European Journal of Drug Metabolism and Pharmacokinetics | 1997
İlkay Küçükgüzel; Mert Ülgen; J. W. Gorrod
SummaryThe metabolism of N-(4-chlorobenzyl)-4-chloroaniline (CBCA), N-(4-chlorobenzyl)-4-chlorobenzylamine (CBCBA), and N-(4-chlorobenzylidene)-4-chlorobenzylamine (CBDCBA) were studied in vitro using rat liver microsomal preparations. The secondary amines produced the corresponding N-oxidation products (hydroxylamines and nitrones) and dealkylation products (4-chlorobenzaldehyde and primary amines). Both secondary amines failed to produce the corresponding amides, whilst the parent imine was detected as a metabonate. CBDCBA, the intermediate imine of CBCBA metabolism, was also incubated under similar conditions. However, no oxaziridine was detected.